Jupiter Neurosciences (JUNS) Other Non-Current Liabilities (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Other Non-Current Liabilities of $84105.0 for Q1 2025, up 31.2% year-over-year from $64105.0 in Q1 2024, and down 86.14% quarter-over-quarter from $606787.0 in Q3 2024.
Jupiter Neurosciences (JUNS) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Other Non-Current Liabilities for 3 consecutive years, with $84105.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Other Non-Current Liabilities rose 31.2% year-over-year to $84105.0; the TTM figure through Mar 2025 stood at $84105.0 (up 31.2% YoY), while the FY2023 annual figure was $1.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities declined to $84105.0 in Q1 2025 per JUNS's latest filing, from $606787.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.5 million in Q4 2023 and bottomed at $64105.0 in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $565098.8 across 3 years, with a median of $345446.0 in 2024.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 31.2% in 2025 and fell as far as 31.2% in 2025.
- Jupiter Neurosciences' Other Non-Current Liabilities stood at $1.5 million in 2023, then slumped by 59.69% to $606787.0 in 2024, then plunged by 86.14% to $84105.0 in 2025.
- Business Quant data shows JUNS's Other Non-Current Liabilities at $84105.0 in Q1 2025, $606787.0 in Q3 2024, and $64105.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 84,105.00 |
| Sep 30, 2024 | 606,787.00 |
| Mar 31, 2024 | 64,105.00 |
| Dec 31, 2023 | 1.51 Mn |